Lantheus Holdings, Inc. (LNTH) company profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic imaging agents and radiopharmaceuticals. The company operates primarily through its radiopharmaceutical oncology and precision diagnostics businesses. Its commercial products include PYLARIFY, an imaging agent used in positron emission tomography scans, DEFINITY, an injectable imaging product, and Neuraceq. In addition, the business develops product candidates such as MK-6240 and NAV-4694. Lantheus serves healthcare providers, clinical development partners, and medical facilities that operate imaging equipment and diagnostic technologies.

The company is headquartered in Bedford, Massachusetts, and is incorporated in Delaware. Lantheus maintains an in-house manufacturing facility as well as an external network of positron emission tomography manufacturing facilities. The company provides products and conducts business activities for customers in the United States and international markets. Its operations also encompass corporate acquisitions, including Life Molecular Imaging and Evergreen Theragnostics.

Summary of the business section of Lantheus's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $6.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 1,193 employees, of which 1,056 were located in the United States and 137 were located internationally.”